EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Breaking Bottlenecks in Continuous Biomanufacturing
Associate Professor, Engineering Product Development, Singapore University of Technology & Research (SUTD)
Shireen Goh Scientific CoFounder of Celltomix and Associate Professor at SUTD is pioneering densesuspension microfluidics to enable clogfree continuous biomanufacturing Her earlier work codeveloped the Erbi microbioreactor acquired by Merck underscoring her track record in academic translation
Articles
Single Domain Antibody
Monoclonal and polyclonal antibodies Abs are wellcorroborated tools adopted in basic biomedical research and innovative key components of numerous therapeutic platforms today on the market The vast majority of the Abs are obtained from easily accessible laboratory animals such as mice hamsters and rabbits and consist of two heavy and two light chains
Research Insights
Mathematical modelling reveals cellular dynamics within tumour spheroids
Tumour spheroids are widely used as an in vitro assay for characterising the dynamics and response to treatment of different cancer cell lines Their popularity is largely due to the reproducible manner in which spheroids grow
Case Studies
Bioavailability of Methadone After Sleeve Gastrectomy: A Planned Observational Case Study
Abstract Although there are no absolute contraindications to bariatric surgery most bariatric surgeons consider that patients with ongoing illicit drug use should not undergo such procedures The lack of clear recommendations within this field makes morbidly obese patients on opioidreplacement therapy a subgroup at risk for treatment refusal There is little
Techno Trends
COMPAS - New Technology for Determining the Cardiac Safety Profile of Drugs
A new technology has been launched to help the pharmaceutical industry better understand the cardiac safety profile of the drugs they are developing It consists of a software called COMPAS which stands for Comprehensive Analysis of Repolarisation Signal and unique ECG Biometrics While the COMPAS software has been developed by the Heart Research Followup Program a part...
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
New Paradigm in Combination Therapy of siRNA with Chemotherapeutic Drugs towards Cancer Targeting
Ruchi is currently designated as Associate Professor, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi-221005, (U.P.), India. Her area of research is nanotechnology based drug delivery systems for targeted delivery of drugs and addressing issues related to conventional dosage forms like poor bioavailability, solubility, higher dose. She has more than 20 publications in international scientific journals including original research articles, reviews and book chapters. e-mail ID – rchawla.phe@iitbhu.ac.in
Krishan Kumar is currently pursuing Ph.D. in Pharmaceutics at Department of Pharmaceutical Engineering, IIT BHU. His research focus on targeted and controlled drug delivery approaches in Nano-therapeutics. He has authored or co-authored 8 publications in international scientific journals in his fields of expertise. He has 2 years 8 months R&D experience in Reckitt Benckiser (India) Ltd. e-mail ID- krishaniskrishan@gmail.com
Varsha Rani is currently Ph.D. research scholar at Department of Pharmaceutical Engineering and Technology, IIT (BHU) Varanasi, India. She is involved in research area focussed on nanocarriers for brain targeted drug delivery system. She has contributed to ten publications including research article, review article and book chapter in reputed scientific journals. She has also done industrial training from Evonik India Pvt. Ltd, Mumbai, India. e-mail ID – varsharani.rs.phe17@itbhu.ac.in
Mohini Mishra is a PhD research scholar at Indian Institute of Technology BHU, Varanasi, India and his area of research is focused on the development of nanoparticulate-based targeted drug delivery systems against BHneurodegenerative diseases. She has authored and co- authored nine publications in international scientific journals and three are in the pipeline. e-mail ID- mohini.mishra0203@gmail.com
Are We Ready to Ship Billions of COVID Vaccines Worldwide?
President, Asia Pacific, Middle East and Africa, FedEx Express
Rethinking How Medicines Work
Dr. Asawari Pagare is a bioinformatician at UW Medicine where she studies the genomics of myositis, an autoimmune disease that is not yet well understood. She earned her PhD in Chemistry from the University of North Carolina at Chapel Hill, USA, where she explored how timing and fluctuations influence how living systems interpret signals relevant to medicine.
Artificial Intelligence - A current and future tool to learn chemical sciences
Ruchi Bharti received her M.Sc. from Patna University, in organic chemistry. PhD from National Institute of Technology Patna (NIT Patna), in 2012. There she worked on the development of new organocatalysts and their utilization in the synthesis of diverse heterocyclic compounds via multimulticomponent reactions. In 2017, she enrolled as assistant professor at R. P Sharma Institute of Technology, Since 2018, she joined Department of Chemistry, University Institute of Sciences, Chandigarh University, Punjab as Assistant Professor. Her recent research work is focused on the functionalisation of diverse heterocycles, multicomponent reactions, organocatalysis and their related biological and medicinal applications.
Multi-Target Directed Ligands and Lipidomics Approach for Glioblastoma Drug Discovery
Dr. Stevan Pecic is an assistant professor at the Department of Chemistry and Biochemistry at California State University, Fullerton. His main research interests and assignments are focused on the identification of novel inhibitors of enzymes involved in lipid metabolism and their evaluation as potential therapeutics in pain management.
Xiaohui Weng earned a bachelor’s in chemistry from Fordham University and recently completed her master’s degree working in Dr. Pecic medicinal chemistry lab at California State University, Fullerton. Her current research focuses on target identification for glioblastoma and the synthesis of new anti-cancer drugs.
Michael Gonzalez is a graduate student pursuing a master’s in chemistry at California State University Fullerton. Currently he also interns at a start-up biotech company, playing an important role in chemistry development for their high-throughput macrocyclic synthesis platform.
Arya obtained his Hon. BSc. in Human kinetics from University of Guelph, where he completed a summer internship at Dr. Ghavami’s lab at University of Manitoba. Arya then pursued a double major from York University majoring in Neuropsychology. Arya’s research under the supervision of Dr. Ghavami resulted in four publications, and he has since been involved in the review and publication process of manuscripts in highly regarded journals. Arya is currently entering the second year of his Doctor of Dental Surgery program at the Faculty of Dentistry, University of Toronto.
Dr. Amir Barzegar Behrooz is a cancer researcher and postdoctoral fellow at the College of Pharmacy, University of Manitoba. His work focuses on various aspects of cancer biology, particularly glioblastoma. His work focuses on targeted cancer therapy, and theranostic targets in cancer cells via Onco-Multi-OMICS.
Dr. Rui Vitorino, Principal Investigator at the University of Aveiro, specializes in OMICS, proteomics, and bioinformatics. His research on biofluids like saliva and urine aims to uncover disease pathways and biomarkers. Vitorino's multidisciplinary approach enhances early disease detection, influencing molecular and cell biology studies significantly.
Dr. Ghavami, an Associate Professor at the University of Manitoba, specializes in apoptosis, autophagy, and unfolded protein response regulation. With over 300 publications and numerous awards, he's globally recognised. Affiliated with institutions worldwide, he serves as Associate Editor for multiple scientific journals.
press releasesRead more...
Insitro Designed Machine Learning Models for Small Molecule in vivo Pharmacokinetic Behavior Prediction Now Available in Lilly TuneLab
Insitro the AI company unlocking causal human biology to systematically generate highimpact therapeutics today announced that the advanced machine learning models that insitro built with Eli Lilly
Lotus Pharmaceutical Announces Completion of UroVaxom® Product Rights Acquisition in South Korea
Lotus Pharmaceutical Co Ltd Taiwan Stock Exchange a global pharmaceutical company headquartered in Taiwan today announced the completion of the acquisition of the South Korea product rights
XtalPi Debuts Kodexia™, the World's First Closed-Loop siRNA Platform Combining Generative AI with First-Principles Modeling
XtalPi Holdings Limited HKEX an AI and roboticsdriven drug and materials discovery company today debuted Kodexia the industrys first closedloop small interfering RNA siRNA
ITOCHU Announces Strengthening of Drug Development Support Through the Use of AI-Driven Drug Discovery Technologies
ITOCHU Corporation announced today that it has signed a capital alliance agreement with MOLCURE Inc headquartered in Kawasaki City Kanagawa Prefecture Satoshi Tamaki Representative Director
GC Cell and QuantHealth Collaborate to Optimize Clinical Development of GCC2005
GC Cell a leader in the cell and gene therapy CGT sector within the biopharmaceutical industry and QuantHealth the global leader in AIpowered clinical trial simulation have announced a collaboratio
EpiSign and Geneyx Announce Partnership to Integrate Genomic and Epigenomic Analysis for Rare Disease
EpiSign Inc and Geneyx Genomex Ltd today announced a partnership to advance the integration of genomic and epigenomic analysis for raredisease interpretation
EventsRead more...
12 - 13
Oct 2026Pharmaceutics 2026
Village Hotel Changi, Singapor...
12 - 13
Oct 20262nd International Conference on Drug Discovery
Village Hotel Changi, Singapor...
14 - 15
Oct 2026PDA Aseptic Manufacturing Excellence Conference
Pullman East Melbourne, Austra...
21 - 23
Oct 2026Drug Formulation & Drug Delivery 2026
Paris, France
21 - 22
Oct 2026Advance Clinical Trials and Research 2026
Paris, France
22 - 23
Oct 2026PDA Aseptic Symposium 2026
Congress Square Nakanoshima, O...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
LATEST NEWSRead more...
Mint Pharmaceuticals and Bayer Expand Medicine Distribution in Canada
Mint Pharmaceuticals and Bayer have expanded their distribution partnership in Canada to include several additional medicines across womens health cardiovascular care and anticoagulation
Halozyme Expands argenx Collaboration to Include Two Additional Development Targets
Halozyme Therapeutics has expanded its global collaboration and licence agreement with argenx to develop and commercialise subcutaneous formulations for two additional exclusive targets using its ENHANZE drug delivery technology
CSL and Alentis Partner to Advance Lixudebart for Rare Kidney and Liver Diseases
CSL and Alentis Therapeutics have entered into a global collaboration to jointly develop and commercialise lixudebart an investigational treatment that targets claudin and could have applications across several kidney liver and other diseases
Regeneron and Sanofi Expand Collaboration to Develop Long-Acting Immunology Antibodies
Regeneron Pharmaceuticals and Sanofi have expanded their longstanding antibody collaboration to develop and commercialise a new group of longacting immunology treatments
SK pharmteco Announces $200 Million Investment to Expand Manufacturing Capacity
SK pharmteco has announced a fiveyear investment of more than million to expand and upgrade its development and manufacturing capabilities in the US focusing on small molecules and peptides
CAS and Novartis Collaborate to Advance AI-Ready Reaction Data
CAS has announced a collaboration with Novartis Biomedical Research to improve access to reaction data and support the use of artificial intelligence in scientific research